Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review

Research output: Contribution to journalLetterpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{b13be5f298e84039863b715fbf9a6f41,
title = "Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review",
abstract = "Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.",
author = "Klarskov, {Carina Kirstine} and {Holm Schultz}, Helga and {Wilbek Fabricius}, Therese and Frederik Persson and Ulrik Pedersen-Bjergaard and {Lommer Kristensen}, Peter",
note = "This article is protected by copyright. All rights reserved.",
year = "2020",
month = aug,
doi = "10.1111/ijcp.13529",
language = "English",
volume = "74",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus

T2 - A Systematic Review

AU - Klarskov, Carina Kirstine

AU - Holm Schultz, Helga

AU - Wilbek Fabricius, Therese

AU - Persson, Frederik

AU - Pedersen-Bjergaard, Ulrik

AU - Lommer Kristensen, Peter

N1 - This article is protected by copyright. All rights reserved.

PY - 2020/8

Y1 - 2020/8

N2 - Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.

AB - Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.

UR - http://www.scopus.com/inward/record.url?scp=85088320971&partnerID=8YFLogxK

U2 - 10.1111/ijcp.13529

DO - 10.1111/ijcp.13529

M3 - Letter

C2 - 32392375

VL - 74

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 8

M1 - e13529

ER -

ID: 59837607